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ScienceDirectTOMMORROW is a Phase III delay of onset clinical trial to
determine whether low doses of pioglitazone, a molecule that
induces mitochondrial doubling, delays the onset of MCI-AD in
normal subjects treated with low dose compared to placebo.
BOLD imaging studies in rodents and man were used to find the
dose that increases oxygen consumption at central regions of
the brain in higher proportion than activation of large corticol
regions. The trial is made practical by the use of a
pharmacogenetic algorithm based on TOMM40 and APOE
genotypes and age to identify normal subjects at high risk of
MCI-AD between the ages of 65–83 years within a five year
follow-up period.
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It is important when discussing genetics and pharmaco-
genetics [PGX] in clinical pharmacology and drug de-
velopment to acknowledge the technologies that are
commonly practiced in drug development. From a
genetics point of view, the contents of clinical pharma-
cology databases for drug metabolites and PK/PD have
certainly been extended by genetic/genomic technol-
ogies over the past two decades. In particular, sequencing
Open access under CC BY-NC-ND license.www.sciencedirect.com of highly polymorphic loci such as the HLA region and
genes involved in drug metabolism have increased speci-
ficity of genetic associations with pharmacokinetic or
pharmacodynamic phenotypes. This expanded compen-
dium of polymorphisms, including less frequent poly-
morphisms, has increased our ability to explore the
genetics of uncommon events in different ethnic groups.
One example is the genetic underpinnings of the hyper-
sensitivity syndrome observed in about 4% of Caucasian
users of abacavir to treat HIV infection [1]. GlaxoWell-
come received an accelerated approval to market abaca-
vir, but approval was accompanied by an expectation by
the FDA and EMA that the company would investigate
the hypersensitivity syndrome. Cooperation throughout
clinical development at GlaxoWellcome was necessary to
undertake the experiments that would allow for the
identification of the subgroup of patients for whom aba-
cavir was contraindicated. While the HLA-B57 locus was
known in 1997, from a database point of view it took
several years to identify the B-5701, 5702 and 5703
polymorphisms at the locus using genomic sequencing.
The risk of the hypersensitivity reaction was present only
in patients with the B-5701 allele.
Today human drug trials provide opportunities to identify
efficacy responders and to characterize their genetics
compared to non-responders [2]. Since very large num-
bers of patients are usually not available [affordable or
practical] as they may be for studies of risk factors for
common diseases studies, the analytical process is a bit
reversed from searching for genetic mutations for Men-
delian disease diagnoses. Patients must be identified and
followed during and after treatment. Predicting efficacy
for individual patients who might also be at risk for an
adverse response will take time to become common in
medicine. Drug trials take years and must be designed to
prospectively evaluate patient responses. A basic require-
ment for genetic testing is that consented DNA samples
must be collected across the entire study. In reality, to
accomplish collection of DNA from all study participants
requires planning and patient consent, without which
pharmacogenetics cannot be used effectively for hypoth-
esis generation, hypothesis testing and for regulatory
decisions.
It is a bit different for uncommon adverse events where
the genetic loci associated with relatively rare, overtCurrent Opinion in Pharmacology 2014, 14:81–89
82 Neurosciencesphenotypes are typically easier to identify. For safety
PGX, the uncommon mutations can be assessed against
population samples, but for efficacy within a trial it is
necessary to study all participants so that efficacy and lack
of efficacy can be compared in participants who received
drug. It is, however, a problem when DNA is not collected
or unavailable in individuals with adverse events. Bank-
ing DNA samples from important studies is still quite
uncommon in the industry [1,14].
The goal of efficacy PGX is to find a genetic biomarker
that predicts high expectation of efficacy in a sufficient
number of people to qualify the test for selection of drug
therapy. These studies focus on the response to treat-
ment, and may be quite distinct from genetic diagnostic
tests for disease. Beginning with any early Phase II
treatment trial, the objective is to differentiate those
treated individuals who respond to the drug but are not
responsive to placebo. This can initially be evaluated in
small studies during which defined clinical responses are
measured. The more obvious the efficacy response, the
more certain early associations can be made. Efficacy
PGX depends on the choice of therapeutic agent, dose,
and the responses of the individuals receiving the drug. It
is also influenced by the type of genetic search performed.
Candidate gene lists involving proposed disease pathways
have provided an effective starting point for translation to
clinical trials for several decades. Genome-wide associ-
ation studies (GWAS) have produced many gene lists
with subsequent rationales provided for selected genes.
To date, there are few examples where specific genes
‘‘discovered’’ by GWAS lists have translated into clini-
cally relevant programs, outside of oncology where
affected tissue is more available to confirm with gene
expression studies.
Each subsequent Phase II trial will provide greater stat-
istical support for markers associated with drug efficacy.
Recently, an investigation of highly polymorphic struc-
tural genes that carry highly polymorphic variations at a
single locus compared to SNPs has reduced the time
necessary for translation to clinical trials [3]. A high
degree of polymorphic variations contribute to the pro-
portion of individuals in a population who are informative
at that locus. Efficacy biomarkers identified and validated
in Phase II may be useful in proof of concept studies and
to stratify and improve the efficiency of Phase III trials.
PGX markers that enrich for responders in Phase III
studies may allow for a more robust efficacy signal and
a faster path to registration. Companion diagnostics can
be also be qualified in late clinical trials to identify
individuals with a higher ‘risk’ of a beneficial response
[3,4]. It should also be noted that polymorphisms in one
ethnic group may be absent or occur at a lower allele
frequency in other ethnic groups. This emphasizes the
need to examine genetic markers carefully in different
ethnicities, especially with highly variable markers [5].Current Opinion in Pharmacology 2014, 14:81–89 This short opinion piece will emphasize some of the
newer genetic technologies that can facilitate Phase III
trial design. Efficacy PGX is a relatively new application
of genetics in clinical development because it requires
DNA collection during the trial. In this new paradigm for
drug development, drug discovery becomes more de-
pendent on studies that utilize these PGX associations.
Safety PGX in the aforementioned abacavir trial demon-
strates the translation of a genetic marker to ensure safer
use of the medication. In addition, economics are often
the major consideration for use of a test, particularly for
defining efficacy for reimbursement. Predicting adverse
responses also leads to extended market use in addition to
enhanced safety long after patent exclusivity for the drug
compound expires. In the case of abacavir it is still used in
HIV drug combinations for HLA-B5701 negative
patients, thereby extending its commercial value after
its chemical patents expired.
New technologies and innovation in a Phase III
clinical trial: trial design to study delay of
onset
Central nervous system [CNS] diseases have recently
experienced declining interest by major drug developers
because the costs of doing clinical studies in these disease
areas can be high and likelihood of approval low. The
basic premise that early clinical pharmacology and safety
studies can rule out [kill fast] compounds works for Phase
I, but there are major differences in the cost of Phase II
and Phase III clinical studies. It can be very costly to run
clinical trials to observe efficacy in a dose-finding trial.
This is especially true for longer trials with clinical end-
points followed over months, such as those performed for
neuropsychiatric disorders.
Studying clinical pharmacology in animals and translating
these findings into human studies is critical for generating
information on dose and trial design that can translate into
reducing overall drug development cost and time to
approval. Imaging technologies have now been applied
to measure effects of different drugs and drug doses on
the pharmacodynamic response of specific anatomical
areas in the brain. While drug dosages are usually pushed
to the highest tolerated level to ensure that efficacy will
not be missed, the chances for adverse events are raised as
well. For neurological diseases, imaging studies in
animals provide a way to determine the most reasonable,
effective dose without waiting for expensive clinical ef-
ficacy studies to define it.
PET and fMRI imaging studies in animals and man can
now be used for dose finding studies in late discovery and
early development, particularly in the neuropsychiatric
diseases from which major pharmaceutical companies
have generally withdrawn over the past five years. These
data can quickly and economically define the lowest dosewww.sciencedirect.com
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dose-finding studies to suggest lower, and generally safer,
brain-active doses in a shorter period of time. This is
particularly relevant to disease prevention studies, where
a drug is used to treat unaffected people at high risk of
developing a particular disease. Dose selection for the
drug that is being used in a delay of onset of Mild
Cognitive Impairment due to Alzheimer’s Disease
[MCI-AD] trial, the TOMMORROW study, was
informed by a BOLD MRI study.
The genetic, imaging and phylogenetic
mapping basis for translation to the
TOMMORROW Phase III clinical trial
The TOMMORROW clinical trial, a large, Phase III trial
to assess delay of onset of MCI-AD in cognitively normal
subjects between 65 and 83 years of age at entry, was
designed to qualify a predictive genetic biomarker in the
context of delaying the onset of MCI-AD using a drug
that may work by increasing the number of mitochondria
in cells. Animal BOLD imaging, which measures anato-
mically specific oxygen utilization during cerebrovascular
response, was used to identify the lowest dose of piogli-
tazone that would activate metabolism in the central areas
of the brain that are associated in humans with clinical AD
[34] (Figure 1).
In order to translate these animal model data to humans,
functional BOLD imaging was conducted following a
memory test in people who received 14 days of pioglita-
zone treatment. BOLD fMRI responses were used for
dose finding studies of pioglitazone using a within-subject
BOLD fMRI paradigm targeting episodic memory-
related hippocampal activation (Figure 2).Figure 1
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An illustration of the experimental results reported in a dose finding experim
connectivity between the CA1 region of the hippocampus and the ventral tha
of pioglitazone, far below the dose usually recommended to treat diabetes m
well below human doses for diabetes mellitus, has diminished central activi
www.sciencedirect.com These BOLD data led to the choice of drug dosage of
0.8 mg/kg for the Phase III TOMMORROW study. The
TOMMORROW trial is designed to qualify the genetic
biomarker, an algorithm composed of TOMM40 and
APOE genotypes and age at study entry, used to identify
those at high risk to develop MCI-AD and simultaneously
test the efficacy of pioglitazone to delay the onset of this
condition in high risk subjects. (Delay of onset trials are
frequently referred to as prevention trials, but to establish
prevention of the condition would require a much longer
study than the 5-year treatment period that is anticip-
ated.) This daily dosage is less than 3% of the dosage
approved for the treatment of type 2 diabetes mellitus.
Pioglitazone boasts a well-documented tolerability record
of more than 22 million man-years of clinical use at the
doses marketed for treatment of type 2 diabetes mellitus
(15–45 mg daily). A lower dose would seem to be safer for
use in normal individuals whose TOMM40 and APOE
genotypes, and age would suggest a higher risk of MCI in
the next five years.
Other genetic technologies
It is important to delineate the other genetic technologies
that led to the TOMM40, APOE, and age-at-entry algor-
ithm that is being qualified. Several years ago, we
suggested using molecular evolutionary analysis [phylo-
genetic mapping] to describe the complex genetics of
neurodegenerative diseases that have a component of
inherited risk to identify clinically useful biomarkers
and disease-associated variants. Across the many GWAS
studies for complex diseases, there were floods of newly
identified ‘disease genes’ with small to moderate (odds
ratio of 1.1–2.0) effect sizes. Still, several years later, many
of the variants identified by GWAS have not been= 0.04 mg/kg D = 0.32 mg/kg
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ent in awake rats using resting state BOLD MRI. Increased functional
lamus and hypothalamus is seen following 7 daily doses with 0.04 mg/kg
ellitus [30–45 mg daily]. Note that the dose of 0.32 mg/kg, which is still
ty.
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An illustration of the results of the human fMRI experiment, demonstrating the activation of oxygen utilization in central regions of the brain usually
affected later by AD. Using this within-subject pharmacologic BOLD fMRI paradigm while testing episodic memory hippocampal activation in the left
hippocampal area was observed, again at a very low dose. At higher pioglitazone doses there is more cortical activity present and less hippocampal
activation observed (Zeineh et al., Science 2003).translated into actionable findings for disease risk predic-
tion or PGX [6,7,8].
Association of APOE4 with increased risk and earlier age
of onset of late-onset AD was first reported in 1993
[9,10]. At this time, the association was widely criti-
cized by AD genetic experts in national and international
meetings, sometimes with presented data later found to
be technically in error. Published reports of relatively
small clinical studies confirmed the association between
APOE genotype and risk of AD [11–16]. Since this time,
multiple GWAS have confirmed that the region contain-
ing APOE is highly significantly associated with risk of
developing AD; spectacular p values were reported for the
association of TOMM40 SNPs within the LD region
containing the APOE gene, for example, in the study
of Harold et al. [17] with four TOMM40 SNPs [including
rs2075650, P = 1.8  10157].
Because the associated SNPs in TOMM40 were located
within the LD region containing APOE, TOMM40’s
strong association with AD was attributed to APOE; that
is, the TOMM40 SNPs were correlated with either the
e4, e3 or e2 epsilon allele SNPs of APOE. In reality, if the
association of APOE4 to AD had not preceded these
GWAS data by more than two decades, TOMM40 may
have been identified as the AD gene instead of APOE
[18,19].
Contrast this with the genetics of the amyloid precursor
protein [APP] region on chromosome 21. Even though
there are rare, autosomal dominant APP mutations, there
is no GWAS support for the amyloid precursor protein
[APP] region on chromosome 21 for sporadic, late-onset
AD [20]. These rare mutations in APP that result in early
onset, autosomal dominant AD have been used, in part, to
justify the huge investment in amyloid research andCurrent Opinion in Pharmacology 2014, 14:81–89 amyloid-associated mechanisms for drug development
programs for late-onset AD [LOAD]. A pathogenetic
mechanism involving these specific APP mutations has
yet to be defined. However, independent of any APP
mutation, it was observed in 2005 that APP protein
truncated at the carboxyl terminus accumulates in the
Tom40 mitochondrial import channel in the brains of AD
patients and this interaction results in mitochondrial dys-
function [21,22].
Early positron emission tomography [PET] data from
several centers demonstrated decreased glucose metab-
olism in brain regions associated with AD pathology in
normal individuals carrying one or both APOE4 alleles
compared to non-APOE4 carriers[23,24,25]. Since the
brain depends on glucose, oxygen and the blood circula-
tion needed to transport them, we investigated a hypoth-
esis that there was something wrong with glucose energy
efficiency and in 1996 began looking at drugs that
increased the number of intracellular mitochondria as
potential treatments [26].
In 1998, SNPs from the PEREC-1 gene next to APOE
within the LD region were determined to be associated
with risk for AD [27]. At that time a function for the
PEREC-1 gene was unknown. In 2002, as a consequence
of the Human Genome Project, PEREC-1 was discov-
ered to be TOMM40 — the outer mitochondrial mem-
brane channel through which peptides and proteins are
imported into mitochondria to support mitochondrial
function and biogenesis [28]. Because TOMM40 is
located immediately adjacent to APOE on the genome,
rather than simply assuming that the association between
TOMM40 and AD just reflected linkage to the corre-
sponding APOE alleles, both TOMM40 and APOE could
be viewed as individually important in a mechanistic
pathway to slowly damage mitochondrial dynamicwww.sciencedirect.com
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disequilibrium and encoded biologically interacting
proteins did not permeate the AD community even after
phylogenetic analyses demonstrated APOE4, APOE3,
and APOE2 alleles were linked to different alleles of a
polyT locus, rs10524523 (henceforth, ‘523’), in intron 6 of
TOMM40. In Caucasians these 523 alleles are defined as
Short (S), Long (L), and Very Long (VL). Genotypes of
the different polyT variant lengths at the 523 locus have
been demonstrated to have different age of onset distri-
butions. The APOE genotypes are fully represented
using TOMM40-523 genotypes (Figure 3).
A group of researchers led by Dr. Yadong Huang at the
Gladstone Institute [San Francisco, CA] investigated the
dynamic functions of mitochondria in neuronal tissue
cultures well before any AD GWAS data were published
[21]. They also investigated the role that intraneuronal
apoE protein isoforms played in these dynamic functions,Figure 3
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Age at onset of cognitive impairment as a function of TOMM40-523
genotype. The Bryan Alzheimer’s Disease Research Center (ADRC)
Memory, Health, and Aging cohort (n = 508, 106 conversion events) was
followed prospectively at the Bryan ADRC at Duke University. Cognitive
status was determined using standard neuropsychological tests. The
age at which cognitive impairment occurred was retrospectively
stratified by TOMM40 genotype, and Kaplan–Meier curves were
constructed. TOMM40 genotype was determined using a sequencing
based genotyping method (Polymorphic DNA Technologies). TOMM40
genotypes and the corresponding APOE genotypes are indicated on the
figure. The red line corresponds to APOE e4/4; the two green lines
correspond to APOE e3/4, and the three blue lines correspond to APOE
e3/3. Note that within this cohort there were 78 individuals who carried
an APOE e2 allele, but only 5 developed cognitive impairment during the
study (VL/L (APOE e2/4), n = 1; S/L (APOE e2/4), n = 2; VL/VL (APOE
e2/3), n = 2). The number of subjects per 523 genotype (number
converted to case status) was: L/L, n = 23 (11); VL/L, n = 54 (24); S/L,
n = 72 (23); S/S, n = 100 (20); S/VL, n = 138 (22); VL/VL, n = 51
(6). Reprinted from [31]. The risk algorithm for qualification in the
TOMMORROW trial is illustrated in Ref. [31].
www.sciencedirect.com including the percentage of intraneuronal mitochondria
moving within a neuron, how far and how fast they moved
down the axon from the cell body to the terminal neurite
area, the differential interaction of apoE4, apoE3, and
apoE2 on these functions, and the effect of mitochondrial
acting drugs in correcting dynamic functions and increas-
ing neurite outgrowth [29,30,31]. Earlier studies had
also demonstrated the interactions of APOE, APP, and
mitochondria [21,22,32].
In 2005, our research team at GlaxoSmithKline initiated
phylogenetic mapping experiments looking directly at
the LD regions on chromosome 19 that contains both
APOE and TOMM40. In 2007, we reported that a 10Kb
region that contains the TOMM40 gene produced a
robust phylogenetic tree structure [33] and we later
validated the phylogenetic tree structure in a different
cohort and further demonstrated that there was a specific
linkage between APOE and TOMM40 alleles (32). In
subsequent experiments, it became clear that the
TOMM40 region containing the intronic, variable polyT
marker, rs10524523, contributed independently of APOE
SNPs to the GWAS association results. Variations in the
polyT lengths differentiated terminal clades on the phy-
logenetic tree and specific polyT lengths were differen-
tially linked to downstream APOE genotypes. For
example the APOE3 allele can be linked to one of two
polyT alleles of rs10524523.
Phylogenetic mapping is a method that is commonly used
to detect new evolutionary mutations in the viral genetics
field. It has been used to map new mutation sites and the
evolution of new strains of influenza viruses so that new
vaccines can be manufactured annually. However, before
the consensus human genome data were available, the
methodology had not been applied to the analysis of
human genetic complex disease loci. It is not a GWAS
methodology, but rather a deep focus on a small region
that has suspected importance. Critically, if a region of the
genome shows low, to no, recombination, the approach is
potentially very powerful for genotype/phenotype associ-
ation analysis, based on the assumption that evolutiona-
rily closely related sequences will share phenotypically
important mutations.
In 2009, the results of two independent phylogenetic
mapping experiments of a small (10 Kb) region of the
genome located within the larger LD region on chromo-
some 19 that contains both the APOE and TOMM40
genes were published [34] (Figure 4). In an IRB-
approved study of AD patients and age matched controls
from a cohort from the Arizona Alzheimer’s Disease
Research Center, DNA was sequenced and underwent
phylogenetic mapping. It was found that virtually all
patients with the APOE4/4 genotype segregated into a
specific branch, named Clade A. Clade B was almost
completely (98%) homogeneous for the APOE3 allele.Current Opinion in Pharmacology 2014, 14:81–89
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Figure 4
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The sub-clades are differentiated by varying lengths of the poly-T allele (i.e. TOMM40-523). APOE3 can be linked to Very Long [Clade A, top red box] or
Short 523 poly-T alleles (Clade B, green box] APOE4 is connected to Long poly-T alleles (Clade A, 2nd and 3rd red boxes,] and a small group of shorter
Long polyT alleles [also Clade A, blue box]. Note especially that the APOE VL [Clade A] and the APOE3 Short [Clade B] clustered separately in distinct
phylogenetic branches.APOE3/3 subjects segregated to both Clades A and B, as
did heterozygotes with the APOE3/4 and APOE2/3 gen-
otypes. The phylogenetic tree was further distinguished
by terminal clades, where clade membership was deter-
mined by the length of the polyT variant, rs10423523, of
TOMM40. The boxes illustrated in Figure 4 show where
polyT length variants from rs10524523 were distributed
in clades by different size ranges. It was found that the
Long [L] polyTs were generally on the same DNA strand
as APOE4, while either a Short [S] or Very Long [VL]
polyT strand was attached to APOE3 or the relatively
uncommon APOE2. Most of the haplotypes containing L
alleles of 523 were located in Clade A, but S or VL alleles
of TOMM40 were attached to APOE3 or APOE2 strands
and were divided to evolutionary-related branches be-
tween Clade A [VL] or Clade B [S]. Since S or VL variants
of 523 were located on the same strands as APOE3 or
APOE2, all other compound APOE genotypes containing
APOE3 or APOE2 alleles were distributed between the
major clades (Figure 3).
A prospective clinical onset study performed over two
decades, with defined age of onset recorded, was
examined retrospectively using the 523 genotypes.
Kaplan–Meier analysis of 523 and APOE genotypes again
showed that the APOE4/4 survival curve was identical toCurrent Opinion in Pharmacology 2014, 14:81–89 523 L/L (Figure 3). The age of onset distribution curves
from a large prospectively collected clinical population
with accurate age of onset ascertainment demonstrated
that the APOE4/4 curve reflected the 523 L/L carriers
[35] (Figure 3). The APOE3/4 distribution now could
be mapped as two age of onset distribution for 523 L-VL
and L-S, and the APOE3/3 and APOE2 carriers were
mapped to three curves, 523 S-S, S-VL or VL-VL. The
523 S or VL alleles attached to APOE2 are similar to
APOE3, but APOE2 carriers shift the age of onset to 8–10
years older. (9) In this way, the phylogenetic mapping
studies were pivotal in being able to elucidate the associ-
ation between TOMM40 rs10524523 variants and risk of
AD at a given age.
Several published studies attempted to simply look at AD
onset data that were not determined from prospective,
longitudinal studies with defined age of onset definitions,
and thus lack the ability to differentiate genetic popu-
lations[36,37]. Figure 3 shows TOMM40 genotype-
specific differences between the rapid decline in the
proportion unaffected by dementia within a decade cen-
tered around 72–75 years of age [35].
Using TOMM40 genotype provides age-dependent risk
prediction for everyone as opposed to the use of APOEwww.sciencedirect.com
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carry APOE 4/4 could an acceptable risk prediction be
made. A biomarker risk algorithm, based on TOMM40
genotype, APOE carriage, and age at presentation has
been developed that determines risk for clinical onset in
97% of the population. [Not enough subjects with the
APOE2/4 or 2/2 genotypes, about 3% of the population,
who developed AD were available from the prospective
Caucasian study to produce the necessary age distribution
curves] [35]. The TOMM40 algorithm derived from the
age of onset distributions will be qualified for clinical
applications during the TOMMORROW study. Using a
validated testing methodology and prospective data, the
clinical validation of the biomarker risk algorithm is one
primary endpoint of the trial [38]. The trial tests a low
dose of pioglitazone, a drug that has the potential to
increase neuronal mitochondrial content [39], to deter-
mine whether it delays the onset of Mild Cognitive
Impairment due to AD in cognitively normal subjects
at high risk of developing disease within the period of the
trial [35,40].
APOE and TOMM40 are in LD and can be clinically
used as a prognostic device in Caucasians. There is great
variability in the spectrum of 523 polyT lengths in other
ethnicities, so studies of the relationship between
TOMM40-523 genotypes and age of MCI of the AD
type, or AD, onset are needed to generalize the risk
algorithm to non-Caucasian ethnicities [5]. Further stu-
dies may demonstrate that each 523 genotype may be
generalized and provide similar risk information across
ethnicities, as is observed in other genetic diseases across
ethnicities [5].
Disease onset prediction using these validated technol-
ogies can only be tested prospectively over time. It is
important to note that the Phase III, TOMMORROW
study, can also be the substrate for traditional efficacy
PGX experiments to identify other specific, relevant
genetic factors that contribute to the response or failure
of response to pioglitazone for the treatment of MCI due
to AD. Thus the efficacy PGX markers for treatment of
MCI due to AD, or AD, in addition to the 523 genotype,
may provide prognostic treatment information for already
affected patients.
A very short follow-up on the use of HLA-
B5701 as an informative test for risk of major
allergic reactions: translation to medical
qualification and the PGX-related data
translating to a marketing success after
patent expiry
Qualification of HLA-B5701 was performed in a Phase III
trial designed to prospectively qualify the marker for
clinical practice. [1] What has not been stated in the
literature is the creation of a commercial bonanza based
on the discovery and qualification of B5701. As HIVwww.sciencedirect.com treatment regimes have progressed to use cocktails of
drugs in combination preparations, the choice of abacavir
to form the reverse-transcriptase function with preferred
safety has led to continued use in formulations, and huge
commercial earnings. The establishment of safety PGX
led to a resurgence of abacavir sales vis-a-vis its newer
competitors that still had no informative diagnostic for
other side effects and adverse events. The subsequent
use of abacavir in combination therapies has far exceeded
the original commercial expectations. This is still the
poster child for human PGX qualified by a prospective
Phase III trial. The approximate cost of the trial was $20
million, while the projected earnings are now extended
well past chemical patent expiry.
In summary, clinical pharmacologic imaging and PGX
uses are becoming intermixed in the vocabulary of drug
development and commercial potential. The safety PGX
that began in 1997, as a condition of accelerated market
approval, revived abacavir use. The benefits of both the
efficacy and safety of abacavir are still a source of com-
mercial value — never anticipated during develop-
ment — and are a victory for PGX by any measure.
The integration of new genetic technologies and PGX
methods into the drug development enterprise is
uncommon, except in cancer and infectious disease
where efficacy can be clinically measured quite accu-
rately and in shorter trials. Multiple genetic technologies
were used to move forward with the TOMMORROW
trial into uncharted drug development territory. Some
very expensive popular technologies, like GWAS, may
have been over-interpreted by the AD field. Hundreds
of new genes have been nominated for disease
associations by borderline statistical scores, yet to date
phylogenetic mapping using quantitative clinical
characteristics of disease has not been widely adopted,
despite translational success. The TOMMORROW trial
will qualify the genetic biomarker and test whether a
known, safe drug given at low dose can be effective in
delaying the onset of MCI due to AD in individuals at
high genetic risk for their specific ages. Prospective
delay of onset studies takes a long time to complete.
In the interim, treatment studies for MCI-AD of shorter
duration are being planned. Applications of phyloge-
netic analyses to other complex diseases of large medical
need, such as obesity and schizophrenia, are currently
underway.
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